Pregnancy: An increase in post-implantation and post-natal losses were observed in a peri- and post-natal study in rats at maternal toxic doses (see Pharmacology: Toxicology: Preclinical safety data under Actions).
There is no data or limited data (less than 300 pregnancies) on the use of tianeptine in pregnant women.
It is therefore preferable to avoid the use of tianeptine during pregnancy, irrespective of the term.
It is preferable to maintain a balanced maternal psychic equilibrium throughout pregnancy. If a drug treatment with tianeptine is required to maintain this equilibrium, the treatment must be started or continued at the effective dose throughout the pregnancy and if possible in monotherapy and the pharmacological profile of the molecule must be taken into account when monitoring the newborn baby.
Lactation: Lactic secretion dysfunction has been observed in rats at materno-toxic doses (see Pharmacology: Toxicology: Preclinical safety data under Actions).
Tricyclic antidepressants are excreted into breast milk, therefore, breast-feeding is not recommended for the duration of the treatment.
Fertility: In rats, a study showed a decrease in the reproductory performance (increase of pre-implantation losses), at materno-toxic doses. (see Pharmacology: Toxicology: Preclinical safety data under Actions).
The clinical impact is unknown.